⚡️⚡️⚡️
With energy prices rising, switch to a cheaper plan
💡
Compare Prices Now
⚡️⚡️⚡️

How to buy Amgen (AMGN) shares in Australia

Learn how to easily invest in Amgen shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Amgen Inc is a drug manufacturers-general business with stocks listed in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$243.09 – an increase of 3.57% over the previous week. Here's how to invest if you're based in Australia.

How to buy shares in Amgen

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Amgen. Find the share by name or ticker symbol: AMGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Amgen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$243.09, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Amgen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Amgen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Amgen stock price (NASDAQ:AMGN)

Use our graph to track the performance of AMGN stocks over time.

Amgen shares at a glance

Information last updated 2022-06-21.
52-week rangeUS$195.3815 - US$257.97
50-day moving average US$245.3334
200-day moving average US$226.6958
Target priceUS$250.03
PE ratio 23.1937
Dividend yield US$7.22 (3.31%)
Earnings per share (TTM) US$10.12

Compare trading apps to buy Amgen shares

1 - 8 of 8
Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, US shares, UK shares, ETFs, and more
Exclusive: Finder customers who apply for a share trading account in June will be able to trade Aussie shares from $2.50 commission until the end of August. T&Cs apply.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Tiger Brokers
Exclusive
Tiger Brokers
US$1.99
N/A
ASX shares, Global shares, Options trading, US shares, ETFs
Exclusive to Finder: Sign up to Tiger through Finder and on completion of your first deposit of any amount or transfer of shares receive 4 extra free grab shares. T&Cs apply.
Get started with $0 brokerage on ASX and US stocks for the first 3 months upon completion of your first qualifying deposit. Also receive a free Apple share if you deposit $3,000 or more.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
Bendigo Invest Direct
$0
0.60%
ASX shares, Global shares, Options trading, mFunds, ETFs, Warrants
Gain access to 12 markets from one account with Bendigo.
Invest in Australian shares and access major international markets through a trusted local brand. Plus, fine tune your investment knowledge with Bendigo’s advanced research and analysis tools.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares, ETFs
Sign up & fund your account with A$100 or more and receive US$10 of Tesla stocks on Superhero. T&Cs apply.
Enjoy $0 brokerage on US stocks and buying ETFs as well as a flat $5 fee to trade Australian shares.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Amgen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Amgen share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Amgen price performance over time

Historical closes compared with the last close of $243.09

1 week (2022-06-17) 3.57%
3 months (2022-03-24) 2.63%
6 months (2021-12-21) 10.04%
1 year (2021-06-25) 0.17%
2 years (2020-06-25) 3.39%
3 years (2019-06-25) 31.80%
5 years (2017-06-23) 40.92%

Is Amgen under- or over-valued?

Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Amgen's P/E ratio

Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Amgen shares trade at around 23x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Amgen's PEG ratio

Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4042. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Amgen's EBITDA

Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$12.9 billion (£10.5 billion).

The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.

Amgen financials

Revenue TTM US$26.3 billion
Operating margin TTM 36.66%
Gross profit TTM US$19.5 billion
Return on assets TTM 9.91%
Return on equity TTM 111.67%
Profit margin 21.75%
Book value 1.715
Market capitalisation US$125.4 billion

TTM: trailing 12 months

Amgen's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Amgen.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Amgen's total ESG risk score

Total ESG risk: 20.95

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Amgen's overall score of 20.95 (as at 01/01/2019) is pretty good – landing it in it in the 24th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Amgen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Amgen's environmental score

Environmental score: 1.53/100

Amgen's environmental score of 1.53 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Amgen's social score

Social score: 15.13/100

Amgen's social score of 15.13 puts it squarely in the 3rd percentile of companies rated in the same sector. This could suggest that Amgen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Amgen's governance score

Governance score: 5.8/100

Amgen's governance score puts it squarely in the 3rd percentile of companies rated in the same sector. That could suggest that Amgen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Amgen's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Amgen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Amgen has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Amgen Inc was last rated for ESG on: 2019-01-01.

Total ESG score 20.95
Total ESG percentile 23.7
Environmental score 1.53
Environmental score percentile 3
Social score 15.13
Social score percentile 3
Governance score 5.8
Governance score percentile 3
Level of controversy 2

Amgen share dividends

42%

Dividend payout ratio: 41.9% of net profits

Recently Amgen has paid out, on average, around 41.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.31% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 3.31% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $7.22 per share.

While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.

Amgen's most recent dividend payout was on 8 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 16 May 2022 (the "ex-dividend date").

Have Amgen's shares ever split?

Amgen's shares were split on a 2:1 basis on 22 November 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.

Amgen share price volatility

Over the last 12 months, Amgen's shares have ranged in value from as little as US$195.3815 up to US$257.97. A popular way to gauge a stock's volatility is its "beta".

AMGN.US volatility(beta: 0.57)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.5726. This would suggest that Amgen's shares are less volatile than average (for this exchange).

Amgen overview

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen in the news

There are no recent company news

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site